...
annx-img

Annexon Inc, Common Stock

ANNX

NSQ

$4.75

-$0.2

(-4.04%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$520.18M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
217.21K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.23
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.65 L
$8.4 H
$4.75

About Annexon Inc, Common Stock

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameANNXSectorS&P500
1-Week Return1.43%-3.39%-3.47%
1-Month Return-9.34%-3.25%-0.29%
3-Month Return-28.57%-11.61%4.5%
6-Month Return-2.37%-5.89%6.91%
1-Year Return78.7%2.65%23.79%
3-Year Return-62.64%0.56%28.43%
5-Year Return-72.13%34.63%83.64%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue493.00K667.00K3.41M3.31M3.27M[{"date":"2019-12-31","value":14.44,"profit":true},{"date":"2020-12-31","value":19.54,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.98,"profit":true},{"date":"2023-12-31","value":95.69,"profit":true}]
Gross Profit(493.00K)(667.00K)(3.41M)(3.31M)(3.27M)[{"date":"2019-12-31","value":-49300000,"profit":false},{"date":"2020-12-31","value":-66700000,"profit":false},{"date":"2021-12-31","value":-341400000,"profit":false},{"date":"2022-12-31","value":-331100000,"profit":false},{"date":"2023-12-31","value":-326700000,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses32.52M63.47M130.71M145.60M143.72M[{"date":"2019-12-31","value":22.33,"profit":true},{"date":"2020-12-31","value":43.59,"profit":true},{"date":"2021-12-31","value":89.78,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.71,"profit":true}]
Operating Income(32.52M)(63.47M)(130.71M)(145.60M)(143.72M)[{"date":"2019-12-31","value":-3251800000,"profit":false},{"date":"2020-12-31","value":-6346900000,"profit":false},{"date":"2021-12-31","value":-13071300000,"profit":false},{"date":"2022-12-31","value":-14559900000,"profit":false},{"date":"2023-12-31","value":-14372300000,"profit":false}]
Total Non-Operating Income/Expense-114.00K780.00K7.30M19.17M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.59,"profit":true},{"date":"2021-12-31","value":4.07,"profit":true},{"date":"2022-12-31","value":38.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(37.18M)(63.41M)(130.32M)(141.95M)(134.24M)[{"date":"2019-12-31","value":-3717900000,"profit":false},{"date":"2020-12-31","value":-6341200000,"profit":false},{"date":"2021-12-31","value":-13032300000,"profit":false},{"date":"2022-12-31","value":-14194700000,"profit":false},{"date":"2023-12-31","value":-13423700000,"profit":false}]
Income Taxes4.00K(667.00K)(2.53M)(3.65M)-[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-16675,"profit":false},{"date":"2021-12-31","value":-63275,"profit":false},{"date":"2022-12-31","value":-91300,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes-(62.74M)(127.79M)(138.29M)-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-6274500000,"profit":false},{"date":"2021-12-31","value":-12779200000,"profit":false},{"date":"2022-12-31","value":-13829500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(37.18M)(63.41M)(130.71M)(145.60M)(140.73M)[{"date":"2019-12-31","value":-3718300000,"profit":false},{"date":"2020-12-31","value":-6341200000,"profit":false},{"date":"2021-12-31","value":-13071300000,"profit":false},{"date":"2022-12-31","value":-14559900000,"profit":false},{"date":"2023-12-31","value":-14072900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(37.18M)(62.74M)(127.79M)(138.29M)(134.24M)[{"date":"2019-12-31","value":-3718300000,"profit":false},{"date":"2020-12-31","value":-6274500000,"profit":false},{"date":"2021-12-31","value":-12779200000,"profit":false},{"date":"2022-12-31","value":-13829500000,"profit":false},{"date":"2023-12-31","value":-13423700000,"profit":false}]
EPS (Diluted)-(33.44)(3.40)(2.87)(1.78)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-3344,"profit":false},{"date":"2021-12-31","value":-340,"profit":false},{"date":"2022-12-31","value":-287,"profit":false},{"date":"2023-12-31","value":-178,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ANNX
Cash Ratio 16.97
Current Ratio 17.18

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ANNX
ROA (LTM) -24.83%
ROE (LTM) -42.20%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ANNX
Debt Ratio Lower is generally better. Negative is bad. 0.12
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.88

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ANNX
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 1.63
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Annexon Inc share price today?

Annexon Inc (ANNX) share price today is $4.75

Can Indians buy Annexon Inc shares?

Yes, Indians can buy shares of Annexon Inc (ANNX) on Vested. To buy Annexon Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANNX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Annexon Inc be purchased?

Yes, you can purchase fractional shares of Annexon Inc (ANNX) via the Vested app. You can start investing in Annexon Inc (ANNX) with a minimum investment of $1.

How to invest in Annexon Inc shares from India?

You can invest in shares of Annexon Inc (ANNX) via Vested in three simple steps:

  • Click on Sign Up or Invest in ANNX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Annexon Inc shares
What is Annexon Inc 52-week high and low stock price?

The 52-week high price of Annexon Inc (ANNX) is $8.4. The 52-week low price of Annexon Inc (ANNX) is $3.65.

What is Annexon Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Annexon Inc (ANNX) is

What is Annexon Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Annexon Inc (ANNX) is 1.63

What is Annexon Inc dividend yield?

The dividend yield of Annexon Inc (ANNX) is 0.00%

What is the Market Cap of Annexon Inc?

The market capitalization of Annexon Inc (ANNX) is $520.18M

What is Annexon Inc’s stock symbol?

The stock symbol (or ticker) of Annexon Inc is ANNX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top